FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296784813> ?p ?o ?g. }

• W2296784813 endingPage "1205" @default.
• W2296784813 startingPage "1200" @default.
• W2296784813 abstract "Essentials•Treatment options are limited for refractory bleeding in acquired von Willebrand Syndrome (AVWS).•Lenalidomide therapy was studied in two patients with AVWS due to monoclonal gammopathy (MG).•Lenalidomide increased von Willebrand factor (VWF), lowered VWF clearance and resolved bleeding.•Lenalidomide is a potential treatment option for refractory bleeding in AVWS secondary to MG.Summary: BackgroundAcquired von Willebrand syndrome (AVWS) is associated with lymphoproliferative disorders, including monoclonal gammopathy (MG) of undetermined significance (MGUS) and multiple myeloma. Patients commonly present with significant bleeding complications that are difficult to manage, owing to a markedly reduced von Willebrand factor (VWF) half‐life.ObjectivesTo investigate the use of the immunomodulatory drug lenalidomide in two patients with severe refractory bleeding caused by AVWS associated with MGs.ResultsIn both patients, lenalidomide treatment resulted in significant clinical improvement, and marked increases in plasma VWF antigen (VWF:Ag) and VWF ristocetin cofactor levels. This normalization in plasma VWF levels was sustained for > 2 years in both patients. Furthermore, in one patient, plasma VWF levels remain normal for at least 14 months following discontinuation of lenalidomide treatment. To investigate the molecular mechanisms underlying these observations, VWF propeptide (VWFpp)/VWF:Ag ratios were analyzed to assess VWF clearance. At enrolment, plasma VWFpp/VWF:Ag ratios were significantly elevated in both patients. Importantly, lenalidomide treatment resulted in normalization of VWFpp/VWF:Ag ratios in both patients. These novel data suggest that lenalidomide functions to attenuate enhanced VWF clearance in AVWS. Interestingly, in a patient with MGUS, lenalidomide treatment was associated with a significant increase in plasma VWF levels, despite no major change in paraprotein level.ConclusionsCollectively, our findings suggest that lenalidomide constitutes a novel therapeutic option for the management of AVWS associated with MG. The biological mechanism(s) through which lenalidomide causes a sustained increase in plasma VWF levels in AVWS independently of paraprotein level requires further study, but is in part modulated through inhibition of enhanced VWF clearance. Essentials•Treatment options are limited for refractory bleeding in acquired von Willebrand Syndrome (AVWS).•Lenalidomide therapy was studied in two patients with AVWS due to monoclonal gammopathy (MG).•Lenalidomide increased von Willebrand factor (VWF), lowered VWF clearance and resolved bleeding.•Lenalidomide is a potential treatment option for refractory bleeding in AVWS secondary to MG. •Treatment options are limited for refractory bleeding in acquired von Willebrand Syndrome (AVWS).•Lenalidomide therapy was studied in two patients with AVWS due to monoclonal gammopathy (MG).•Lenalidomide increased von Willebrand factor (VWF), lowered VWF clearance and resolved bleeding.•Lenalidomide is a potential treatment option for refractory bleeding in AVWS secondary to MG. Acquired von Willebrand syndrome (AVWS) is associated with lymphoproliferative disorders, including monoclonal gammopathy (MG) of undetermined significance (MGUS) and multiple myeloma. Patients commonly present with significant bleeding complications that are difficult to manage, owing to a markedly reduced von Willebrand factor (VWF) half‐life. To investigate the use of the immunomodulatory drug lenalidomide in two patients with severe refractory bleeding caused by AVWS associated with MGs. In both patients, lenalidomide treatment resulted in significant clinical improvement, and marked increases in plasma VWF antigen (VWF:Ag) and VWF ristocetin cofactor levels. This normalization in plasma VWF levels was sustained for > 2 years in both patients. Furthermore, in one patient, plasma VWF levels remain normal for at least 14 months following discontinuation of lenalidomide treatment. To investigate the molecular mechanisms underlying these observations, VWF propeptide (VWFpp)/VWF:Ag ratios were analyzed to assess VWF clearance. At enrolment, plasma VWFpp/VWF:Ag ratios were significantly elevated in both patients. Importantly, lenalidomide treatment resulted in normalization of VWFpp/VWF:Ag ratios in both patients. These novel data suggest that lenalidomide functions to attenuate enhanced VWF clearance in AVWS. Interestingly, in a patient with MGUS, lenalidomide treatment was associated with a significant increase in plasma VWF levels, despite no major change in paraprotein level. Collectively, our findings suggest that lenalidomide constitutes a novel therapeutic option for the management of AVWS associated with MG. The biological mechanism(s) through which lenalidomide causes a sustained increase in plasma VWF levels in AVWS independently of paraprotein level requires further study, but is in part modulated through inhibition of enhanced VWF clearance." @default.
• W2296784813 created "2016-06-24" @default.
• W2296784813 creator A5000884311 @default.
• W2296784813 creator A5007517961 @default.
• W2296784813 creator A5027672455 @default.
• W2296784813 creator A5044126660 @default.
• W2296784813 creator A5050070662 @default.
• W2296784813 creator A5055945057 @default.
• W2296784813 creator A5067116422 @default.
• W2296784813 creator A5074712719 @default.
• W2296784813 creator A5084128881 @default.
• W2296784813 date "2016-06-01" @default.
• W2296784813 modified "2023-10-10" @default.
• W2296784813 title "Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy" @default.
• W2296784813 cites W1587685635 @default.
• W2296784813 cites W1594485137 @default.
• W2296784813 cites W1785732432 @default.
• W2296784813 cites W1969059748 @default.
• W2296784813 cites W1992838420 @default.
• W2296784813 cites W1999680744 @default.
• W2296784813 cites W2004777016 @default.
• W2296784813 cites W2017534212 @default.
• W2296784813 cites W2036927323 @default.
• W2296784813 cites W2039848757 @default.
• W2296784813 cites W2061214127 @default.
• W2296784813 cites W2063408037 @default.
• W2296784813 cites W2081389709 @default.
• W2296784813 cites W2092164518 @default.
• W2296784813 cites W2092322834 @default.
• W2296784813 cites W2115047246 @default.
• W2296784813 cites W2120738206 @default.
• W2296784813 cites W2140665265 @default.
• W2296784813 cites W2145463995 @default.
• W2296784813 cites W2270373849 @default.
• W2296784813 cites W2460657058 @default.
• W2296784813 cites W298319700 @default.
• W2296784813 cites W4247535347 @default.
• W2296784813 doi "https://doi.org/10.1111/jth.13317" @default.
• W2296784813 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26991062" @default.
• W2296784813 hasPublicationYear "2016" @default.
• W2296784813 type Work @default.
• W2296784813 sameAs 2296784813 @default.
• W2296784813 citedByCount "21" @default.
• W2296784813 countsByYear W22967848132016 @default.
• W2296784813 countsByYear W22967848132017 @default.
• W2296784813 countsByYear W22967848132018 @default.
• W2296784813 countsByYear W22967848132019 @default.
• W2296784813 countsByYear W22967848132020 @default.
• W2296784813 countsByYear W22967848132021 @default.
• W2296784813 countsByYear W22967848132022 @default.
• W2296784813 countsByYear W22967848132023 @default.
• W2296784813 crossrefType "journal-article" @default.
• W2296784813 hasAuthorship W2296784813A5000884311 @default.
• W2296784813 hasAuthorship W2296784813A5007517961 @default.
• W2296784813 hasAuthorship W2296784813A5027672455 @default.
• W2296784813 hasAuthorship W2296784813A5044126660 @default.
• W2296784813 hasAuthorship W2296784813A5050070662 @default.
• W2296784813 hasAuthorship W2296784813A5055945057 @default.
• W2296784813 hasAuthorship W2296784813A5067116422 @default.
• W2296784813 hasAuthorship W2296784813A5074712719 @default.
• W2296784813 hasAuthorship W2296784813A5084128881 @default.
• W2296784813 hasBestOaLocation W22967848131 @default.
• W2296784813 hasConcept C121332964 @default.
• W2296784813 hasConcept C126322002 @default.
• W2296784813 hasConcept C142424586 @default.
• W2296784813 hasConcept C143998085 @default.
• W2296784813 hasConcept C159654299 @default.
• W2296784813 hasConcept C163864487 @default.
• W2296784813 hasConcept C203014093 @default.
• W2296784813 hasConcept C2776063141 @default.
• W2296784813 hasConcept C2776364478 @default.
• W2296784813 hasConcept C2777250017 @default.
• W2296784813 hasConcept C2779394231 @default.
• W2296784813 hasConcept C542903549 @default.
• W2296784813 hasConcept C71924100 @default.
• W2296784813 hasConcept C87355193 @default.
• W2296784813 hasConcept C89560881 @default.
• W2296784813 hasConcept C90924648 @default.
• W2296784813 hasConceptScore W2296784813C121332964 @default.
• W2296784813 hasConceptScore W2296784813C126322002 @default.
• W2296784813 hasConceptScore W2296784813C142424586 @default.
• W2296784813 hasConceptScore W2296784813C143998085 @default.
• W2296784813 hasConceptScore W2296784813C159654299 @default.
• W2296784813 hasConceptScore W2296784813C163864487 @default.
• W2296784813 hasConceptScore W2296784813C203014093 @default.
• W2296784813 hasConceptScore W2296784813C2776063141 @default.
• W2296784813 hasConceptScore W2296784813C2776364478 @default.
• W2296784813 hasConceptScore W2296784813C2777250017 @default.
• W2296784813 hasConceptScore W2296784813C2779394231 @default.
• W2296784813 hasConceptScore W2296784813C542903549 @default.
• W2296784813 hasConceptScore W2296784813C71924100 @default.
• W2296784813 hasConceptScore W2296784813C87355193 @default.
• W2296784813 hasConceptScore W2296784813C89560881 @default.
• W2296784813 hasConceptScore W2296784813C90924648 @default.
• W2296784813 hasIssue "6" @default.
• W2296784813 hasLocation W22967848131 @default.
• W2296784813 hasLocation W22967848132 @default.
• W2296784813 hasOpenAccess W2296784813 @default.

• next